Zürcher Nachrichten - AstraZeneca moves some production to US amid tariff threat

EUR -
AED 4.106389
AFN 78.818229
ALL 98.550917
AMD 433.76762
ANG 2.000837
AOA 1025.193701
ARS 1264.990691
AUD 1.739051
AWG 2.012376
AZN 1.902847
BAM 1.949299
BBD 2.260203
BDT 136.007051
BGN 1.953741
BHD 0.421433
BIF 3281.291051
BMD 1.117987
BND 1.451984
BOB 7.735411
BRL 6.304217
BSD 1.119387
BTN 95.396458
BWP 15.198588
BYN 3.663349
BYR 21912.539898
BZD 2.248542
CAD 1.56256
CDF 3208.622173
CHF 0.940914
CLF 0.027421
CLP 1052.283208
CNY 8.056604
CNH 8.0615
COP 4703.090674
CRC 568.514285
CUC 1.117987
CUP 29.626648
CVE 109.89753
CZK 24.929962
DJF 198.68854
DKK 7.461287
DOP 65.793587
DZD 149.010876
EGP 56.334907
ERN 16.769801
ETB 148.624943
FJD 2.538048
FKP 0.842009
GBP 0.842973
GEL 3.063551
GGP 0.842009
GHS 13.919172
GIP 0.842009
GMD 81.051047
GNF 9677.293385
GTQ 8.600013
GYD 234.1932
HKD 8.724383
HNL 28.787736
HRK 7.532325
HTG 146.472851
HUF 403.246684
IDR 18524.425215
ILS 3.973923
IMP 0.842009
INR 95.574505
IQD 1464.562616
IRR 47081.221819
ISK 145.137269
JEP 0.842009
JMD 178.664189
JOD 0.792991
JPY 163.96837
KES 144.782901
KGS 97.768141
KHR 4494.306495
KMF 492.333415
KPW 1006.216549
KRW 1577.423135
KWD 0.343915
KYD 0.932806
KZT 568.693171
LAK 24162.516557
LBP 100171.610611
LKR 334.187045
LRD 223.152685
LSL 20.426169
LTL 3.301124
LVL 0.676259
LYD 6.159823
MAD 10.398955
MDL 19.522246
MGA 5064.480324
MKD 61.487521
MMK 2347.082197
MNT 3999.761415
MOP 8.998553
MRU 44.327796
MUR 51.317926
MVR 17.272916
MWK 1940.825081
MXN 21.672597
MYR 4.805076
MZN 71.444311
NAD 20.425656
NGN 1789.404469
NIO 41.085954
NOK 11.618621
NPR 152.642697
NZD 1.896661
OMR 0.430411
PAB 1.119337
PEN 4.103036
PGK 4.546013
PHP 62.456344
PKR 315.243135
PLN 4.23309
PYG 8937.196171
QAR 4.070147
RON 5.104055
RSD 116.822509
RUB 89.849789
RWF 1603.481383
SAR 4.193169
SBD 9.340069
SCR 15.892258
SDG 671.347602
SEK 10.91131
SGD 1.455255
SHP 0.878562
SLE 25.376455
SLL 23443.622963
SOS 638.930361
SRD 40.695273
STD 23140.068094
SVC 9.794512
SYP 14535.732744
SZL 20.425489
THB 37.363512
TJS 11.602416
TMT 3.918543
TND 3.380239
TOP 2.618436
TRY 43.356081
TTD 7.576868
TWD 33.936376
TZS 3017.928064
UAH 46.472623
UGX 4089.362762
USD 1.117987
UYU 46.764051
UZS 14522.647288
VES 104.378209
VND 28989.395896
VUV 134.301269
WST 3.117582
XAF 653.788437
XAG 0.034758
XAU 0.000351
XCD 3.021415
XDR 0.821315
XOF 643.96075
XPF 119.331742
YER 272.956853
ZAR 20.388668
ZMK 10063.249381
ZMW 29.804408
ZWL 359.991271
  • JRI

    -0.1100

    12.77

    -0.86%

  • NGG

    -0.1000

    67.43

    -0.15%

  • BCC

    -2.9700

    90.74

    -3.27%

  • CMSD

    -0.1300

    22.26

    -0.58%

  • RELX

    0.6600

    53.06

    +1.24%

  • RIO

    -0.2400

    62.03

    -0.39%

  • RBGPF

    63.8100

    63.81

    +100%

  • CMSC

    -0.0950

    21.965

    -0.43%

  • SCS

    -0.1700

    10.54

    -1.61%

  • GSK

    -0.1300

    36.22

    -0.36%

  • RYCEF

    -0.1700

    10.53

    -1.61%

  • VOD

    -0.0200

    9.04

    -0.22%

  • AZN

    -1.4900

    66.23

    -2.25%

  • BCE

    -0.7200

    21.26

    -3.39%

  • BTI

    -0.1400

    40.55

    -0.35%

  • BP

    -0.2000

    30.36

    -0.66%

AstraZeneca moves some production to US amid tariff threat
AstraZeneca moves some production to US amid tariff threat / Photo: Jonathan NACKSTRAND - AFP/File

AstraZeneca moves some production to US amid tariff threat

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.

Text size:

"Our company is firmly committed to investing and growing in the US," chief executive Pascal Soriot said in an earnings statement, which also reported that first-quarter profit rose by over 30 percent to $2.92 billion.

The United States earlier in April opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to Trump's sweeping levies on imports from trading partners.

Trump has also imposed a series of sector-specific levies, slapping tariffs on imports of steel, aluminium and autos, before launching a "national security" investigation into pharmaceutical imports.

AstraZeneca could become exposed to US levies on its European-made products but Soriot stressed that the impact would be limited due to the ongoing shift in production.

"The limit of the exposure we have relates to exporting products from Europe to the US," Soriot said on an earnings call.

"We are in the process of shifting the manufacturing of those products to the US," he added.

The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3.5 billion there by the end of 2026.

Soriot said earlier in the year that he hoped the US will account for around half of AstraZeneca's global revenue by 2030.

Other pharmaceutical companies have also announced plans to increase investments in the United States.

AstraZeneca reconfirmed its outlook on Tuesday, saying it remains on track to achieve its target of $80 billion in annual revenue by the end of the decade.

Its first-quarter profit in 2025 benefited from strong growth in its cancer drug sales and biopharmaceuticals.

During the quarter, it generated 42 percent of its revenue in the United States, followed by 20 percent in Europe.

M.Hug--NZN